Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Enterprise Value (2020 - 2025)

Foghorn Therapeutics has reported Enterprise Value over the past 6 years, most recently at -$82.1 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$82.1 million for Q4 2025, down 48.1% from a year ago — trailing twelve months through Dec 2025 was -$82.1 million (down 48.1% YoY), and the annual figure for FY2025 was -$82.1 million, down 48.1%.
  • Enterprise Value for Q4 2025 was -$82.1 million at Foghorn Therapeutics, up from -$90.6 million in the prior quarter.
  • Over the last five years, Enterprise Value for FHTX hit a ceiling of -$50.6 million in Q1 2023 and a floor of -$213.6 million in Q1 2022.
  • Median Enterprise Value over the past 5 years was -$72.1 million (2023), compared with a mean of -$83.2 million.
  • Biggest five-year swings in Enterprise Value: tumbled 1829.97% in 2021 and later soared 76.3% in 2023.
  • Foghorn Therapeutics' Enterprise Value stood at -$101.1 million in 2021, then surged by 48.37% to -$52.2 million in 2022, then tumbled by 53.86% to -$80.3 million in 2023, then soared by 30.97% to -$55.5 million in 2024, then tumbled by 48.1% to -$82.1 million in 2025.
  • The last three reported values for Enterprise Value were -$82.1 million (Q4 2025), -$90.6 million (Q3 2025), and -$73.8 million (Q2 2025) per Business Quant data.